(CADASIL) Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy

The PI of this project is:

This project is funded by: NIH

The term of this project is: March 2022 to August 2024

The number of subjects scanned during this project is: 20

CADASIL is the most common heritable cause of vascular dementia, but many of the early symptoms of the disease remain poorly understood. This study is designed to look at how a person’s body, brain, and behavior change throughout the stages of this disease, and what factors might serve as additional risks or protective factors.

This is not a treatment study, it is a study to develop the best methods for future clinical care and clinical trials for experimental treatments. Researchers will use the information and samples to prepare data for review by the Critical Path Institute in concert with the Food and Drug Administration so future treatments can be delivered to persons with the CADASIL gene at the best time possible.

This study is being done at over a dozen institutions in the United States. A total of 500 people will participate in this study.

Participants will complete: a clinical interview, a neurological exam, neurocognitive and behavior assessments, MRI, and a blood draw at each study visit.

Funding for this study is provided by the National Institutes of Health (NIH). This means that the study site is receiving payments from NIH to support the activities that are required to conduct the study. No one on the research team has or will receive a direct payment or increase in salary from NIH for conducting this study.